Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT02462837

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:39:07.565675+00:00

Published At

2023-06-13T00:00:00+00:00

Record Updated At

2023-06-13

Results Posted At

2023-06-13

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Urinary Bladder, Overactive", "Pain", "Lower Urinary Tract Symptoms"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2023-06-13"

protocolSection.identificationModule.nctId

"NCT02462837"

protocolSection.identificationModule.officialTitle

"Myrbetriq\u2122 (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement"

protocolSection.statusModule.overallStatus

"TERMINATED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

"2023-06-13"

Study condition terms

• Urinary Bladder, Overactive (protocolSection.conditionsModule.conditions)
• Pain (protocolSection.conditionsModule.conditions)
• Lower Urinary Tract Symptoms (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.